Moreover, a series of studies by Shepherd and colleagues showed that the combination of AKT inhibition and autophagy blockade may effectively reduce the number of residual EOC cells that can contribute to ovarian cancer recurrence22–24. This evidence concerns the gene AKT1 and ovarian carcinoma.